No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 39 of the 40 quarters in the window, leaving 1 comparable quarter; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T21:47:34.181Z. Latest historical point 2025-11-05.
The latest delayed quote for Minerva Neurosciences, Inc. (NERV) stock was $3.43 as of Oct 6, 2026, 4:00 PM EDT, up 3.31% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +57.8% · 3-year avg -18.9%/yr · 5-year avg -22.1%/yr
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system.
Biotechnology · Burlington, MA
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.14
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.14
vs Estimate
$-0.19
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1NERV | $159.80M | $3.43 | +3.31% | +57.75% | -22.14% | -29.77% | N/A |
| 2PEPG | $159.78M | $2.31 | -2.12% | -53.83% | N/A | N/A | vs NERV |
| 3LFMDP | $159.22M | $23.35 | +2.14% | +6.17% | +10.80% | N/A | vs NERV |
| 4CHRS | $159.14M | $1.03 | -8.04% | -31.58% | -41.38% | -26.92% | vs NERV |
| 5QTRX | $162.04M | $3.44 | -9.71% | -37.20% | -39.63% | N/A | vs NERV |
| 6INGN | $156.22M | $5.77 | -2.86% | -31.21% | -32.83% | -20.74% | vs NERV |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 3 analysts
Average Price Target
$10.33
+201.3% upside
Low
$7.00
Current
$3.43
High
$14.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Quarter ending Dec 2026 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Quarter ending Mar 2027 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Quarter ending Jun 2027 | $-0.19 | $-0.19 | $-0.19 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.52 | $-2.52 | $-2.52 | 1 |
| FY 2027 | $-0.68 | $-0.68 | $-0.68 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $19.76M | $19.76M | $19.76M | 3 |
| FY 2027 | $56.49M | $56.49M | $56.49M | 3 |
